Vimal Mehta

BioXcel Corp. is a biopharmaceutical company based in Branford, CT that utilizes advanced technologies such as AI to develop transformative medicines at unprecedented speed in multiple therapeutic areas with high unmet needs. BioXcel's AI-enabled platform, EvolverAI, helps reduce development costs and accelerates the drug development timelines for a technologically-enabled, fast and efficient drug discovery process. The private company's family of companies includes BioXcel Therapeutics, Inc., which is a biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing AI and its approaches. BioXcel is deeply involved in creating breakthroughs in various categories of diseases. The company was founded by Vimal D. Mehta and Krishnan Nandabalan, with Vimal D. Mehta serving as the CEO since incorporation.

Invea Therapeutics, Inc. operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its products include INVA8001 and INVA8003. The company was founded on October 20, 2021. The company is headquartered in Guilford, CT.

Part of Jubilant Pharmova Ltd., Jubilant Life Sciences (USA), Inc. is a company that wholesales pharmaceuticals. The company is based in Bedminster, NJ.

Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom.

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.